GT Medical Technologies, Inc., a Tempe, AZ-based medical system firm raised extra $16M in Sequence D funding.
Backers included FemHealth Ventures and Warren Level Capital.
The corporate intends to make use of the funds to drive the enlargement of its U.S. industrial actions for GammaTile.
Led by CEO Per Langoe, GT Medical Applied sciences gives GammaTile, which is a type of radiation remedy positioned on the time of mind tumor removing surgical procedure, delivering fast, focused radiation to the tumor web site when most cancers cells are at their lowest ranges. By delivering fast, localized radiation straight on the tumor web site, it’s designed to optimize the remedy’s effectiveness towards remaining most cancers cells to scale back the chance of regrowth.
To this point, greater than 1,900 sufferers have been handled with GammaTile Remedy, and over 800 sufferers have been enrolled in GammaTile medical research.
Earlier this yr, GT Medical Applied sciences introduced the completion of a $37M first shut of the Sequence D fairness financing led by Evidity Well being Capital, alongside new investor Accelmed Companions and present traders MVM Companions, Gilde Healthcare, and Medtech Enterprise Companions.
The elevate introduced the full quantity to $53M.
FinSMEs
15/07/2025
